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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 9, Revision 3 
(FGE.09Rev3): 
Secondary alicyclic saturated and unsaturated alcohols, ketones and esters 
containing secondary alicyclic alcohols from chemical group 8 and 30, and 
an ester of a phenol derivative from chemical group 251 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 17 flavouring substances in the Flavouring Group 
Evaluation 9, Revision 3, using the Procedure in Commission Regulation (EC) No 1565/2000. None 
of the substances were considered to have genotoxic potential. The substances were evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that the 16 substances [FL-no: 02.070, 02.075, 02.135, 02.167, 06.136, 
07.203, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] do not 
give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. For the remaining candidate substance [FL-no: 07.207] additional toxicity data are 
requested (further metabolism and/or toxicity studies). Besides the safety assessment of these 
flavouring substances, the specifications for the materials of commerce have also been considered. 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2011-01052, EFSA-Q-2011-01051, EFSA-Q-2011-00858, 
adopted on 29 September 2011. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Leon Brimer, Laurence Castle, Karl-Heinz Engel, Roland 
Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude Lhuguenot, 
Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Fidel Toldra, Detlef Wölfle. 
 Correspondence: cef-unit@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, 
Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard 
Mulder, Karin Nørby, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the preparatory 
work on this scientific Opinion. 
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Specifications including complete purity criteria and identity for the materials of commerce have been 
provided for all 17 candidate substances. 
© European Food Safety Authority, 2011 
SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate one flavouring substance in the 
Flavouring Group Evaluation 9, Revision 3 (FGE.09Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. The flavouring substance belongs to chemical group 08, 
Annex I of the Commission Regulation (EC) No 1565/2000. 
The present flavouring group evaluation therefore deals with 17 secondary alicyclic saturated and 
unsaturated alcohols, ketones, one hemiketal ester and esters containing secondary alicyclic alcohols. 
The flavouring substances are structurally related to 27 flavouring substances evaluated at the 51st, 59th 
and 63rd meetings of the Joint FAO/WHO Expert Committee on Food Additives (the JECFA). 
Fourteen of the flavouring substances have one or more chiral centres. For all of these substances, the 
stereoisomeric composition has been specified. 
Thirteen of the flavouring substances belong to structural class I, three belong to structural class II, 
and one to structural class III, according to the decision tree approach presented by Cramer et al., 
1978. 
Ten of the flavouring substances have been reported to occur naturally in a wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach 16 flavouring substances in this group have intakes in 
Europe ranging from 0.0012 to 110 microgram/capita/day, which are all below their respective 
threshold of concern value for structural class I, II or III of 1800, 540 or 90 microgram/person/day, 
respectively. For one substance [FL-no: 09.520] from structural class II the MSDI is 770 
microgram/capita/day, which is above the threshold of concern of 540 microgram/person/day. 
Genotoxicity data are available only for a limited number of the flavouring substances in the present 
group and the genotoxicity cannot be assessed adequately as it is now. However, the data available do 
not indicate a genotoxic potential and therefore do not preclude their evaluation via the Procedure. 
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Sixteen of the flavouring substances are expected to be metabolised to innocuous products at the 
estimated levels of use as flavouring substances. The remaining substance, cyclotetradecanone, could 
not be assumed to be metabolised to innocuous products due to lack of data on cyclotetradecanone or 
on closely related substances. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that, on the basis of the default MSDI approach, 16 of the 17 candidate substances 
would not give rise to safety concerns at the estimated levels of intake arising from their use as 
flavouring substances. For one flavouring substance, cyclotetradecanone [FL-no: 07.207], the 
evaluation has been deferred as additional data on toxicokinetics and/or toxicology are required. 
When the estimated intakes were based on the mTAMDI approach they ranged from 420 to 38000 
microgram/person/day for 12 of the 13 flavouring substances in structural class I. For seven [FL-no: 
02.070, 02.075, 02.135, 02.167, 09.355, 09.621 and 09.870], the mTAMDI is below the threshold of 
concern of 1800 microgram/person/day and for five [FL-no: 09.154, 09.618, 09.619, 09.935 and 
09.949] above the threshold. For one flavouring substance [FL-no: 09.929] from structural class I the 
use levels are missing. The estimated intakes of the three substances [FL-no: 07.203, 07.207 and 
09.520] assigned to structural class II, based on the mTAMDI, are 1600, 3900 and 3900 
microgram/person/day, respectively, which are all above the threshold of concern for structural class II 
substances of 540 microgram/person/day. The mTAMDI estimate for the one substance from 
structural class III [FL-no: 06.136] is 0.075 microgram/person/day, which is below the threshold of 90 
microgram/person/day.  
The substances [FL-no: 02.070, 02.075, 02.135, 02.167, 06.136, 09.355, 09.621 and 09.870], which 
have mTAMDI estimates below the threshold of concern, are also expected to be metabolised to 
innocuous products. 
Thus, for eight flavouring substances [FL-no: 07.203, 07.207, 09.154, 09.520, 09.618, 09.619, 09.935 
and 09.949], and for [FL-no: 09.929] for which use levels are missing, more reliable exposure data are 
required. On the basis of such additional data, these flavouring substances should be reconsidered 
along the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Specifications including 
complete purity criteria and identity for the materials of commerce have been provided for all 17 
flavouring substances. 
For cyclotetradecanone [FL-no: 07.207] additional toxicity data are requested (further metabolism 
and/or toxicity studies). For the remaining 16 substances [FL-no: 02.070, 02.075, 02.135, 02.167, 
06.136, 07.203, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] 
the Panel concluded that they would present no safety concern at the estimated levels of intake based 
on the MSDI approach. 
KEYWORDS 
Flavourings, alcohols, ketones, esters, secondary alicyclic, saturated, unsaturated, food safety, 
FGE.09. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
The Flavouring Group Evaluation 09, FGE.09 dealt with nine secondary alicyclic saturated and 
unsaturated alcohols, ketones and esters containing secondary alicyclic alcohols, and one ester of a 
phenol carboxylic acid and a secondary alicyclic alcohol. In total 10 candidate substances. 
The first Revision of FGE.09, FGE.09Rev1, included the assessment of five additional flavouring 
substances [FL-no: 06.136, 09.154, 09.520, 09.929 and 09.935]. No new toxicity or metabolism data 
were provided for four of the five substances. For [FL-no: 09.520] acute and short term toxicity data 
and in vitro and in vivo genotoxicity data have been provided. Additional data on five substances [FL-
no: 02.075, 02.167, 09.355, 09.619 and 09.621] was made available since the FGE.09 was published. 
The second Revision of FGE.09, FGE.09Rev2, included the assessment of one additional candidate 
substance, carvyl-3-methylbutyrate [FL-no: 09.870]. No toxicity and/or metabolism data were 
provided for this substance. Carvyl-3-methylbutyrate has initially been considered in FGE.212 with 
respect to genotoxicity, together with other alpha,beta-unsaturated substances from subgroup 2.6 of 
FGE.19, where the Panel concluded “d-Carvone [FL-no: 07.146] was found genotoxic in vitro. 
However, d-carvone was not carcinogenic in mice. Therefore, the Panel concluded that this substance 
together with the structurally related l-carvone as well as carveol and the carvylderivatives [FL-no: 
02.062, 07.147, 09.143, 09.215 and 09.870] could be evaluated through the Procedure.”. 
 
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.09 9 December 2004 http://www.efsa.eu.int/science/afc/afc_opinions/814_en.html 10 
FGE.09Rev1 1 April 2008 http://www.efsa.europa.eu/en/efsajournal/doc/927.pdf  15 
FGE.09Rev2 13 May 2009 http://www.efsa.europa.eu/en/efsajournal/pub/1454.htm 16 
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The present Revision of FGE.09, FGE.09Rev3, includes the assessment of one additional candidate 
substance, L-menthyl (S)-3-hydroxybutyrate [FL-no: 09.949]. No data were provided by Industry for 
this substance. A search in open literature for this substance did not provide any further data on 
toxicity or metabolism. 
Furthermore, Industry has provided use levels for [FL-no: 06.136] (Flavour Industry, 2010k). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
After the finalisation of the evaluation programme, in their letter of the 12th April 2010, the 
Commission requested EFSA to carry out an evaluation of the flavouring substance L-menthyl (S)-3-
hydroxybutyrate [FL-no: 09.949], also according to Commission Regulation (EC) No 1565/2000 (EC, 
2000a). 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 9, Revision 3 
1.1. Description 
The present Flavouring Group Evaluation (FGE.09Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (the Procedure – shown in schematic form in Annex I of 
this FGE), deals with six secondary alicyclic saturated and unsaturated alcohols, ketones, one 
hemiketal ester and 10 esters containing secondary alicyclic alcohols. These 17 flavouring substances 
belong to chemical groups 08, 25 and 30 of Annex I of Regulation (EC) No 1565/2000 (EC, 2000a).  
The flavouring substances (candidate substances) are structurally related to 27 flavouring substances 
(supporting substances) evaluated at the 51st, 59th and 63rd meetings of the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) in the groups “Substances structurally related to menthol”, 
“Carvone and structurally related substances”, “Alicyclic ketones, secondary alcohols and related 
esters” and “Monocyclic and bicyclic secondary alcohols, ketones and related esters” (JECFA, 1999a; 
JECFA, 2003a; JECFA, 2006a). Furthermore the racemate of menthyl-3-hydroxybutyrate has been 
evaluated by the JECFA at the 69th meeting (JECFA, 2009a) in the group of “Substances structurally 
related to menthol”. The racemate is not in the Register. 
The candidate substances under consideration, as well as their chemical Register names, FLAVIS- 
(FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufacturers Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
The outcome of the Safety Evaluation is summarised in Table 2a. 
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The hydrolysis products of the candidate substances and their evaluation status as flavouring 
substances are listed in Table 2b. 
The names and structures for the 27 supporting substances are listed in Table 3, together with their 
evaluation status. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
One candidate substance possesses one chiral centre [FL-no: 07.203] and 13 substances possess two or 
more chiral centres [FL-no: 02.075, 02.167, 06.136, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 
09.870, 09.929, 09.935 and 09.949]. For these 14 substances the stereoisomeric composition has been 
specified. 
1.3. Natural Occurrence in Food 
Ten candidate substances [FL-no: 02.070, 02.075, 02.135, 02.167, 07.203, 09.154, 09.355, 09.520, 
09.618 and 09.619] have been reported to occur in fruits, spices, butter, chicken, wine, drinks, tea, 
juice and essential oils. Quantitative data on the natural occurrence of these substances in food have 
been reported for four of these ten substances (TNO, 2000). 
These reports include: 
• Cyclohexanol [FL-no: 02.070]: up to 0.1 mg/kg in fruits (passionfruit) and 0.006 mg/kg in 
white wine 
• Isodihydrocarveol [FL-no: 02.167]: trace amounts in spices (caraway seed) 
• Neo-dihydrocarveol [FL-no: 02.075]: trace amounts in spices (caraway seed) 
• Cyclopentanol [FL-no: 02.135]: 0.01–0.1 mg/kg in passiflora juice, 0.01–0.1 mg/kg in 
passiflora mollisima, 0.01–0.02 mg/kg in oysters and 0.01 mg/kg in chinese quince flesh. 
According to TNO (TNO, 2000; TNO, 2010), the remaining seven candidate substances have not been 
reported to occur naturally in any food items. These seven substances are menthyl salicylate [FL-no: 
09.621], 6-isopropyl-3,9-dimethyl-1,4-dioxyspiro[4.5]decan-2-one [FL-no: 06.136], 
cyclotetradecanone [FL-no: 07.207], carvyl-3-methylbutyrate [FL-no: 09.870], L-monomenthyl 
glutarate [FL-no: 09.929], dimenthyl glutarate [FL-no: 09.935] and L-menthyl (S)-3-hydroxybutyrate 
[FL-no: 09.949].  
2. Specifications 
Purity criteria for the 17 candidate substances have been provided by the Flavouring Industry (see 
Table 1 (EFFA, 2003a; EFFA, 2010a; Flavour Industry, 2004h; Flavour Industry, 2006c; Flavour 
Industry, 2006o; Flavour Industry, 2010f). Judged against the requirements in Annex II of 
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Commission Regulation (EC) No 1565/2000 (EC, 2000a), the specifications are adequate for all 17 
substances (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present FGE.09Rev3, the total annual volume of production of the 17 candidate substances from 
use as flavouring substances in Europe has been reported to be approximately 8000 kg (EFFA, 2003a; 
EFFA, 2003b; Flavour Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; Flavour 
Industry, 2010f; Flavour Industry, 2010k). For the 26 of 27 supporting substances, for which 
production figures are available, the total annual volume of production is approximately 138500 kg 
(JECFA, 1999a; JECFA, 2003a; JECFA, 2006a). 
On the basis of the annual volumes of production reported for the 17 candidate substances, the MSDI 
values for each of these flavourings have been estimated (Table 2a). 
Nearly 99 % of the total annual volumes of production for the candidate substances is accounted for 
by five of these flavourings, 6-isopropyl-3,9-dimethyl-1,4-dioxyspiro[4.5]decan-2-one [FL-no: 
06.136], methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520], L-monomenthyl glutarate [FL-
no: 09.929], dimenthyl glutarate [FL-no: 09.935] and L-menthyl (S)-3-hydroxybutyrate [FL-no: 
09.949]. The estimated daily per capita intakes from use as flavouring substances are 12, 770, 110, 30 
and 37 microgram, respectively. The daily per capita intakes for each of the remaining substances are 
less than 4 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels5,6,7 were submitted by the Flavour Industry (EFFA, 2003a; Flavour Industry, 
2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; EFFA, 2007a; Flavour Industry, 2010f; 
Flavour Industry, 2010k). For L-monomenthyl glutarate [FL-no: 09.929] the use has not been reported 
in accordance with the food categories as outlined in Annex III of Commission Regulation (EC) No 
1565/2000. For the remaining 16 candidate substances the use in flavoured food products divided into 
the food categories as outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 
2000a), is shown in Table 3.1.  
For the present calculation of mTAMDI, the reported normal use levels were used. In the case where 
different use levels were reported for different food categories the highest reported normal use level 
was used. 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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Table 3.1 Use of Candidate Substances in Various Food Categories for 17 Candidate Substances for which 
Data on Use have been provided  
Food 
category 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 All 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 09.949] 
03.0 Edible ices, including sherbet and sorbet All 
04.1 Processed fruits All except [FL-no: 06.136] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses 
and legumes), and nuts & seeds 
Only [FL-no: 09.935] 
05.0 Confectionery All 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, 
pulses & legumes, excluding bakery 
All except [FL-no: 09.935] 
07.0 Bakery wares All 
08.0 Meat and meat products, including poultry and game All except [FL-no: 06.136 and 
09.949] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 06.136 and 
09.949] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 06.136] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 09.935 and 
09.949] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All except [FL-no: 09.870] 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All 
15.0 Ready-to-eat savouries All except [FL-no: 06.136]  
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
All 
* No adequate use levels have been submitted for [FL-no: 09.929] 
According to the Flavour Industry the normal use levels for the 16 candidate substances, for which 
Industry has provided data on food categories and normal and maximum use level are in the range of 
0.0001 - 100 mg/kg food, and the maximum use levels are in the range of 0.0001 - 1500 mg/kg food 
(EFFA, 2003a; Flavour Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; EFFA, 
2007a; Flavour Industry, 2010f; Flavour Industry, 2010k). For L-monomenthyl glutarate [FL-no: 
09.929] no use levels in the food categories as outlined in Annex III of Commission Regulation (EC) 
No 1565/2000 have been provided.  
The mTAMDI values for 12 of the 13 candidate substances from structural class I (see Section 5) 
range from 420 to 38000 microgram/person/day. For the three candidate substances from structural 
class II the mTAMDI values are 1600, 3900 and 3900 microgram/person/day, respectively. For the 
remaining substance from structural class III the mTAMDI is 0.075 microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
The 10 esters [FL-no: 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 
09.949] included in this FGE are expected to be hydrolysed to the corresponding carboxylic acids and 
alcohols, based on the evaluation of supporting substances (Emberger, 1994a; Emberger, 1994b; 
White et al., 1990). The resulting carboxylic acids are either metabolised through common 
physiological pathways like beta-oxidation and the citric acid cycle or excreted in conjugation with 
glucuronide (Keefer et al., 1987; Vree et al., 1994) (see Table 2b and Annex III). 
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The one hemiketal ester [FL-no: 06.136] is expected to be hydrolysed to the corresponding cyclic 
ketone, p-menthan-3-one [FL-no: 07.176] and lactic acid [FL-no: 08.004]. 
One of the main pathways for the candidate alcohols and the ketones (after reduction) [FL-no: 02.070, 
02.075, 02.135, 02.167, 07.203 and 09.520] is conjugation with glucuronic acid followed by 
excretion. Menthol, carveol and dihydrocarveol, the hydrolysis products of [FL-no: 06.136, 09.154, 
09.355, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] are also metabolised via this 
pathway. Neither menthol nor carveol is anticipated to be oxidised to the corresponding ketone (for 
detailed discussion, see Annex III). 
Additional pathways involved in the metabolism of the candidate substances are reduction of ketone 
groups, oxidation of alkyl groups of alkyl substituted alicyclic ketones followed by conjugation with 
glucuronic acid and/or sulphates resulting in excretion (see Annex III). Thus, it may be anticipated that 
these 16 substances will be metabolised to innocuous products. 
No information is available on toxicokinetics (including metabolism) of cyclotetradecanone [FL-no: 
07.207] or on structurally related substances. Cyclotetradecanone [FL-no: 07.207] cannot be assumed 
to be metabolised to innocuous products. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 17 candidate substances the Procedure was applied. The stepwise 
evaluations are summarised in Table 2a. 
Step 1 
Thirteen of the candidate substances are classified into structural class I [FL-no: 02.070, 02.075, 
02.135, 02.167, 09.154, 09.355, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949], three 
candidate substances [FL-no: 07.203, 07.207 and 09.520] into structural class II and one substance 
[FL-no: 06.136] is classified into structural class III according to the decision tree approach presented 
by Cramer et al. (Cramer et al., 1978). 
Step 2 
Step 2 requires consideration of whether detoxification pathways are available to metabolise the 
substances, at the estimated levels of intake, to innocuous products. 
Sixteen of the candidate substances [FL-no: 02.070, 02.075, 02.135, 02.167, 06.136, 07.203, 09.154, 
09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] are expected to be 
metabolised to innocuous products and accordingly they proceed via the A-side of the Procedure 
scheme (Annex I). 
It cannot be anticipated that cyclotetradecanone [FL-no: 07.207] is metabolised to innocuous products 
and accordingly it proceeds via the B-side. 
Step A3 
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The 13 candidate substances [FL-no: 02.070, 02.075, 02.135, 02.167, 09.154, 09.355, 09.618, 09.619, 
09.621, 09.870, 09.929, 09.935 and 09.949] that have been assigned to structural class I have 
estimated European daily per capita intakes ranging from 0.0012 to 110 microgram (Table 2a). These 
intakes are below the threshold of concern of 1800 microgram/person/day for structural class I. 
The two candidate substances [FL-no: 07.203 and 09.520] assigned to structural class II have 
European daily per capita intakes of 0.0085 and 770 microgram, respectively (Table 2a). For [FL-no: 
07.203] the intake is below the threshold of concern of 540 microgram/person/day for structural class 
II. For [FL-no: 09.520] the daily per capita intake of 770 microgram is above the threshold of concern 
for a substance assigned to structural class II. The substance therefore proceeds to step A4.  
The candidate substance [FL-no: 06.136] has been assigned to structural class III and has a European 
daily per capita intake of 12 microgram. This intake is below the threshold of concern of 90 
microgram/person/day for structural class III. 
Based on the results of the safety evaluation sequence, 15 candidate substances [FL-no: 02.070, 
02.075, 02.135, 02.167, 06.136, 07.203, 09.154, 09.355, 09.618, 09.619, 09.621, 09.870, 09.929, 
09.935 and 09.949] proceeding via the A-side of the Procedure do not pose a safety concern when 
used at estimated levels of intake, based on the MSDI approach, as flavouring substances.  
Step A4 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] or its metabolites are not endogenous, 
the substance therefore proceeds to step A5. 
Step A5 
A 90 day study in rats has been performed for [FL-no: 09.520] from which a No Observed Adverse 
Effect Level (NOAEL) of 100 mg/kg body weight (bw)/day could be derived. This NOAEL provides 
a margin of safety of nearly 104 compared to the daily intake of 0.013 mg/kg bw/day for methyl 3-
oxo-2-pentyl-1-cyclopentylacetate. Therefore, [FL-no: 09.520] does not pose a safety concern when 
used at estimated levels of intake, based on the MSDI approach, as flavouring substance. 
Step B3 
The estimated intake (MSDI) for cyclotetradecanone [FL-no: 07.207] of 0.061 microgram/capita/day 
does not exceed the threshold of concern for structural class II (540 microgram/person/day). 
Accordingly, the evaluation proceeds to step B4. 
Step B4 
Toxicity studies that would permit establishment of a NOAEL are not available for cyclotetradecanone 
[FL-no: 07.207] or for structurally related substances. 
Therefore, for the candidate substance cyclotetradecanone [FL-no: 07.207] additional data are 
required. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes, based on the mTAMDI, range from 420 to 38000 microgram/person/day for 12 
of the 13 candidate substances in structural class I. For seven of these 12 substances [FL-no: 02.070, 
02.075, 02.135, 02.167, 09.355, 09.621 and 09.870] the mTAMDI is below the threshold of concern 
of 1800 microgram/person/day and for five substances [FL-no: 09.154, 09.618, 09.619, 09.935 and 
09.949] above the threshold. For L-monomenthyl glutarate [FL-no: 09.929] no use levels in the food 
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categories as outlined in Annex III of Commission Regulation (EC) No 1565/2000 have been 
provided. 
For the three substances [FL-no: 07.203, 07.207 and 09.520] assigned to structural class II, the 
estimated intakes, based on the mTAMDI, are 1600, 3900 and 3900 microgram/person/day, 
respectively, which are all above the threshold of concern for structural class II substances of 540 
microgram/person/day.  
For [FL-no: 06.136], assigned to structural class III, the estimated intake based on the mTAMDI is 
0.075 microgram/person/day, which is below the threshold of concern for a structural class III 
substance of 90 microgram/person/day. 
Thus, for eight candidate substances [FL-no: 07.203, 07.207, 09.154, 09.520, 09.618, 09.619, 09.935 
and 09.949] further information is therefore required. This would include more reliable intake data and 
then, if required, additional toxicological data. For L-monomenthyl glutarate [FL-no: 09.929] use 
levels are needed in accordance with the food categories as outlined in Annex III of Commission 
Regulation (EC) No 1565/2000. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 6.1. 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.070 Cyclohexanol 3.7 1600 Class I 1800 
02.075 neo-Dihydrocarveol 2.4 1600 Class I 1800 
02.135 Cyclopentanol 0.012 1600 Class I 1800 
02.167 Isodihydrocarveol 2.4 1600 Class I 1800 
09.154 Menthyl valerate 1.0 3900 Class I 1800 
09.355 neo-Dihydrocarvyl acetate 0.012 1600 Class I 1800 
09.618 Menthyl formate 0.73 3900 Class I 1800 
09.619 Menthyl hexanoate 0.37 3900 Class I 1800 
09.621 Menthyl salicylate 0.012 420 Class I 1800 
09.870 Carvyl-3-methylbutyrate 0.0012 1000 Class I 1800 
09.929 L-Monomenthyl glutarate 110  Class I 1800 
09.935 Dimenthyl glutarate 30 38000 Class I 1800 
09.949 L-Menthyl (S)-3-hydroxybutyrate 37 10600 Class I 1800 
07.203 3,3,5-Trimethylcyclohexan-1-one 0.0085 1600 Class II 540 
07.207 Cyclotetradecanone 0.061 3900 Class II 540 
09.520 Methyl 3-oxo-2-pentyl-1-cyclopentylacetate 770 3900 Class II 540 
06.136 6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one 
12 0.075 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003a; Flavour Industry, 
2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; EFFA, 2007a; Flavour Industry, 2010f; 
Flavour Industry, 2010k), the combined estimated daily per capita intake as flavourings of the 13 
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candidate substances assigned to class I is 190 microgram, which does not exceed the threshold of 
concern for a compound belonging to structural class I of 1800 microgram/person/day. 
The candidate substances from structural class I are structurally related to 15 supporting substances for 
which European intake data are available (European intake data are only available for 15 of the 16 
supporting substances from structural class I). The total combined intake of the 13 candidate and 15 
supporting substances is approximately 16500 microgram/capita/day, which is above the threshold for 
structural class I substances of 1800 microgram/person/day. The major contribution (98 %) is provided 
by one supporting substance, menthol [FL-no: 02.015] (16 mg/capita/day). An ADI of 0-4 mg/kg bw 
was allocated to menthol (JECFA-no: 427) at the 51st meeting (JECFA, 2000a). The ADI is 15 times 
higher that the MSDI of 16 mg/capita/day. The total combined daily per capita intake for the 
remaining substances from structural class I is approximately 500 microgram, which is below the 
threshold for structural class I of 1800 microgram/person/day. 
On the basis of the reported annual production volumes in Europe, the total estimated daily per capita 
intake as flavourings of the three candidate substances assigned to structural class II is 770 microgram, 
which exceeds the threshold of concern for a compound belonging to structural class II of 540 
microgram/person/day. Nearly 100 % of the 770 microgram derives from one candidate substance, 
namely methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520]. However, for methyl 3-oxo-2-
pentyl-1-cyclopentylacetate a NOAEL of 100 mg/kg bw/day has been established, which provides a 
margin of safety of more than 7000 to the daily per capita intake of 770 microgram, corresponding to 
13 microgram/kg bw/day. For the remaining two substances the combined daily per capita intake is 
below 1 microgram, which is below the threshold of 540 microgram/person/day for a structural class II 
substance. 
The total combined intake from the three candidate and 11 supporting substances from structural class 
II is approximately 1700 microgram/capita/day, which exceeds the threshold for structural class II 
substances of 540 microgram/person/day. The major contribution (97 %) is provided by one candidate 
substance, methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] and one supporting substance, 
trans-menthone [FL-no: 07.176]. The estimated intake of [FL-no: 09.520] of 770 
microgram/capita/day corresponds to 13 microgram/kg bw/day, which is more than 7000 fold lower 
than the NOAEL of 100 mg/kg bw/day for methyl 3-oxo-2-pentyl-1-cyclopentylacetate. Likewise, the 
estimated intake of [FL-no: 07.176] of 890 microgram/capita/day corresponds to 15 microgram/kg 
bw/day, which is nearly 27.000 fold lower than the NOAEL of 400 mg/kg bw/day for trans-menthone. 
The total combined daily per capita intake for the remaining 12 candidate and supporting substances 
from structural class II is approximately 40 microgram, which is below the threshold for structural 
class II of 540 microgram/person/day. 
The only candidate substance from structural class III, 6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one has a daily per capita intake of 12 microgram, which does not exceed the 
threshold of 90 microgram/person/day. There are no supporting substances from structural class III. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for five candidate substances [FL-no: 02.070, 02.135, 06.136, 09.520 and 09.355]. 
Oral LD50 values from studies in the rat range from 625 mg/kg body weight (bw) to > 5000 mg/kg bw.  
Ten supporting substances [FL-no: 02.015, 02.061, 02.062, 02.209, 07.111, 07.148, 07.176, 09.016, 
09.215 and 09.216] were tested for acute toxicity in the mouse, rat, rabbit and guinea pig. The LD50 
values ranged from 930 mg/kg bw to > 5000 mg/kg bw. 
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The magnitudes of the LD50 values indicate that the oral acute toxicity is rather low for the candidate 
substances and supporting substances. 
All acute toxicity studies are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Only one conventional subchronic oral study has been conducted on the candidate substances. For 
cyclohexanol [FL-no: 02.070] data were available from a study designed to investigate only peripheral 
neuropathy in which rats were given intraperitoneal doses of 200 mg cyclohexanol once or twice daily 
for up to six weeks. No effects on the peripheral nervous system were observed but the experiment 
was terminated early because the animals were in poor condition, there was a decrement of weight 
gain and two animals died prematurely. No general gross or histopathological examinations were 
reported and no No Observed Adverse Effect Level (NOAEL) was established. This study was not 
considered applicable to the evaluation of the oral toxicity of cyclohexanol (Perbellini et al., 1981). 
For methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] a study, following the current OECD 
guidelines, was performed in rats. Male and female Sprague-Dawley CD rats were given in the diet 
daily doses of 0 (basal diet), 10, 50 or 100 mg/kg bw over a 90-day period (10 male and 10 female rats 
per dose group). No treatment related changes were observed in mortality, expanded clinical 
observations, ophthalmic examination, body weight gain, body weight change, food consumption, 
haematology, clinical chemistry, urinalysis, organ weights and macroscopic examination. There were 
no treatment related histopathological changes in the tissues from rats of any of the treatment groups. 
The NOAEL was therefore considered to be 100 mg/kg bw/day (the highest dose tested) (Kelly and 
Bolte, 2000). 
Carcinogenicity studies are available for the two supporting substances cyclohexanone and menthol 
[FL-no: 07.148 and 02.015].  
Cyclohexanone [FL-no: 07.148] was given to male and female rats in the drinking water (3300 and 
6500 ppm) and male and female mice (6500, 13000 and 25000 ppm (only female)) for two years. A 
reduction in weight gain (15 - 20 %) was observed in all groups at the highest doses. An increase in 
the incidence of lymphomas was observed at a lower dose level, but it was not dose related (Lijinsky 
and Kovatch, 1986).  
In two other studies, two doses of dl-menthol were given to rats in the diet (3750 and 7500 ppm) and 
mice (2000 and 4000 ppm) for 103 weeks. A small reduction in survival was seen in the treated female 
mice. An increase of incidence of mammary gland fibroadenomas or mammary adenocarcinomas was 
observed in female rats at the lower dose level, but this was not dose related. In male rats, dl-menthol 
was not considered toxic or carcinogenic. In mice, a small increase in the incidence of hepatocellular 
carcinomas was observed. However, this increase was within the normal range of tumour incidence in 
the historical control groups, and the authors concluded that dl-menthol was not carcinogenic in rats 
and mice in the performed studies (National Cancer Institute, 1979). 
For five supporting substances [FL-no: 02.015, 07.095, 07.111, 07.176 and 07.148] there are further 
oral subchronic toxicity data.  
The repeated-dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
There is a study available for one candidate substance [FL-no: 02.070], with a NOAEL of < 1500 
mg/kg bw/day. For one supporting substance [FL-no: 02.015] there are several studies (see Annex IV, 
Table IV.3). 
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The developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Genoxicity data are available for only three candidate substances cyclohexanol [FL-no: 02.070], 
cyclopentanol [FL-no: 02.135], methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] and for 
nine supporting substances and one structurally related substance.  
.Cyclohexanol [FL-no: 02.070] was not genotoxic in two Ames tests and in an in vivo micronucleus 
assay, which are all considered as valid studies. However, the results of the in vivo study are of limited 
relevance, due to lack of evidence that the substance did reach the bone marrow. Inconclusive results 
were reported in an in vitro chromosomal aberration assay with human leukocytes and negative results 
were reported in a dominant lethal mutations assay with Drosophila melanogaster; both studies were 
considered inadequate. Cyclopentanol [FL-no: 02.135] was studied in a valid Ames test. No 
mutagenicity was observed. 
A battery of in vitro and in vivo genotoxicity studies were conducted on methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [FL-no: 09.520] including valid negative reverse mutation tests in Escherichia coli 
(Wagner and Klug, 2000) and Salmonella typhimurium (Thompson, 2000). 
In a mouse lymphoma test, pre-dating GLP, a more than 2-fold increase of the mutant frequency over 
the solvent treated control values was found at the highest tested cytotoxic concentration of 300 µg/ml 
in the presence of metabolic activation, and at the two highest tested cytotoxic concentrations of 200 
and 300 µg/ml in the absence of metabolic activation. Only limited documentation is provided in the 
study report; together with the fact that several cultures were infected and a lack of a confirmatory test, 
it is impossible to assess the reliability of these results (Ross and Harris, 1979b).  
No induction of forward mutations at the TK locus in L5178Y mouse lymphoma cells were found in a 
study performed in compliance with the current OECD test guidelines, both in the absence and in the 
presence of metabolic activation, up to and including cytotoxic concentrations (Cifone, 2001).  
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was tested in a bone marrow micronucleus test in mice 
following a single intraperitoneal administration of 0, 280, 560 or 1120 mg/kg bw in corn oil. The 
study was performed in compliance with the current OECD test guidelines. The two highest doses 
chosen induced clear signs of toxicity; slight reductions (up to 12 %) in the ratio of polychromatic 
erythrocytes to total erythrocytes were found, indicating that the test material had reached the target 
cells. No increase in micronucleated cells was found in the groups treated with the test material. The 
positive control induced the expected increases (Gudi and Krsmanovis, 1998). 
In an Unscheduled DNA Synthesis (UDS) study, the ability of methyl 3-oxo-2-pentyl-1-
cyclopentylacetate to induce DNA repair was studied in isolated rat hepatocytes after administration in 
vivo. The study was performed in compliance with the current OECD Guideline 486 (OECD, 1997). 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was administered to male Sprague-Dawley CD rats by 
intra-peritoneal injection in doses of 333.3 and 1000 mg/kg bw (the latter dose was the maximum 
tolerated dose) followed by liver perfusion at 2 or 16 hours after dosing. No marked increase in the 
incidence of UDS was observed at either dose level or perfusion time. Statistically significant 
differences were revealed in the positive control groups when compared to the negative control group 
and the test article (Durward, 2001). 
Genotoxicity data are available for nine supporting substances [FL-no: 02.015, 02.062, 07.148, 
07.176, 09.027, 09.215, 09.230, 07.149 and 07.045]. 
Cyclohexanone [FL-no: 07.148], structurally related to the alicyclic ketones and secondary alcohols in 
this FGE, was not mutagenic in an Ames test, considered to be valid. Negative and positive results 
were reported in several other in vitro studies at gene and chromosomal level, as well as a negative 
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result in a sex-linked recessive lethal mutations in D. melanogaster. However, these studies were 
considered inadequate.  
Menthol [FL-no: 02.015] gave negative results in an in vitro alkaline elution assay for detecting DNA 
single strand breaks in rat hepatocytes. With the same substance equivocal results in an in vivo host 
mediated mutation assay were observed at high dose levels and negative results in several Ames tests, 
a TK+/- mouse lymphoma assay, sister chromated exchange (SCE) tests in Chinese hamster ovary 
(CHO) cells and human lymphocytes, and chromosomal aberration assays with human embryonic lung 
cells, human lymphocytes and CHO cells. Negative results were also reported in two in vivo 
micronucleus and chromosomal aberration assays. However, the results of these studies have a limited 
relevance, due to the lack of bone marrow toxicity. In addition, an in vivo dominant lethal assay was 
available, from which also negative results were obtained. trans-Menthone [FL-no: 07.176] was 
genotoxic in an Ames test and in a somatic mutation and recombination test (SMART) with 
Drosophila. The observed effects were not very pronounced. Further, trans-menthone is easily 
converted to menthol, which is estimated to be overall negative in genotoxicity tests. 
Carveol and carvyl acetate [FL-no: 02.062 and 09.215] were tested in Ames test at various doses from 
10 - 560 µg/plate in the Salmonella typhimurium strains TA97, TA98, TA100, TA1535 and TA1537 
with and without S9 mix in dimethyl sulphoxide. Positive and negative controls were used. No 
mutagenicity was observed. (Mortelmans et al., 1986). 
Conclusion on genotoxicity  
Only for three of the candidate substances some genotoxicity data are available, and for these three 
mainly negative results were obtained. For the supporting substances mainly negative, but also some 
positive results were obtained. The positive results were obtained in poorly reported tests, or in tests, 
which are difficult to interpret with respect to their relevance for genotoxicity. 
Overall, the genotoxic potential of this group of flavouring substances cannot be fully assessed as it is 
now. However, the data available do not indicate a genotoxic potential and therefore do not preclude 
their evaluation via the Procedure. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The present Revision of FGE.09, FGE.09Rev3 includes the assessment of one additional candidate 
substance, L-menthyl (S)-3-hydroxybutyrate [FL-no: 09.949], compared to FGE.09Rev2.  
So, the present FGE deals with 17 secondary alicyclic saturated and unsaturated alcohols, ketones, one 
hemiketal ester and esters containing secondary alicyclic alcohols. These 17 flavouring substances 
belong to chemical groups 8, 25 and 30 of Annex I of Regulation (EC) No 1565/2000.  
One candidate substance [FL-no: 07.203] possesses one chiral centre and 13 substances [FL-no: 
02.075, 02.167, 06.136, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 
09.949] possess two or more chiral centres. For these 14 substances the stereoisomeric composition 
has been specified.  
Thirteen of the candidate substances belong to structural class I, three substances [FL-no: 07.203, 
07.207 and 09.520] belong to structural class II, and one to structural class III [FL-no: 06.136], 
according to the decision tree approach presented by Cramer et al., 1978. 
Ten of the flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
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According to the default MSDI approach 16 flavouring substances in this group have intakes in 
Europe ranging from 0.0012 to 110 microgram/capita/day, which are all below their respective 
threshold of concern value for structural class I, II or III of 1800, 540 or 90 microgram/person/day, 
respectively. For one substance [FL-no: 09.520] from structural class II the MSDI is 770 
microgram/capita/day, which is above the threshold of concern of 540 microgram/person/day. 
The total combined intakes of candidate and supporting substances from structural class I and II do not 
give rise to safety concern. 
Genotoxicity data are available only for a limited number of the flavouring substances in the present 
group and the genotoxicity cannot be assessed adequately as it is now. However, the data available do 
not indicate a genotoxic potential and therefore do not preclude their evaluation via the Procedure. 
Sixteen of the candidate substances are expected to be metabolised to innocuous products at the 
estimated levels of use as flavouring substances. The remaining candidate substance, 
cyclotetradecanone [FL-no: 07.207], could not be assumed to be metabolised to innocuous products 
due to lack of data on cyclotetradecanone or on closely related substances. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present FGE using the Procedure. 
It is considered that, on the basis of the default MSDI approach, 16 candidate substances would not 
give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. For one candidate substance, cyclotetradecanone [FL-no: 07.207], the evaluation has been 
deferred as additional data on toxicokinetics and/or toxicology are required. 
When the estimated intakes were based on the mTAMDI approach they ranged from 420 to 38000 
microgram/person/day for 12 of the 13 candidate substances in structural class I. For seven [FL-no: 
02.070, 02.075, 02.135, 02.167, 09.355, 09.621 and 09.870], the mTAMDI is below the threshold of 
concern of 1800 microgram/person/day and for five [FL-no: 09.154, 09.618, 09.619, 09.935 and 
09.949] above the threshold. For one flavouring substance [FL-no: 09.929] from structural class I the 
use levels are missing. The estimated intakes of the three substances [FL-no: 07.203, 07.207 and 
09.520] assigned to structural class II, based on the mTAMDI, are 1600, 3900 and 3900 
microgram/person/day, respectively, which are all above the threshold of concern for structural class II 
substances of 540 microgram/person/day. The mTAMDI estimate for the one substance from 
structural class III [FL-no: 06.136] is 0.075 microgram/person/day, which is below the threshold of 90 
microgram/person/day.  
The substances [FL-no: 02.070, 02.075, 02.135, 02.167, 06.136, 09.355, 09.621 and 09.870] which 
have mTAMDI estimates below the threshold of concern are also expected to be metabolised to 
innocuous products. 
Thus, for eight candidate substances [FL-no: 07.203, 07.207, 09.154, 09.520, 09.618, 09.619 09.935 
and 09.949] and for [FL-no: 09.929] for which use levels are missing, more reliable exposure data are 
required. On the basis of such additional data, these flavouring substances should be reconsidered 
along the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Specifications including 
complete purity criteria and identity for the materials of commerce have been provided for all 17 
candidate substances.  
For cyclotetradecanone [FL-no: 07.207] additional toxicity data are requested (further metabolism 
and/or toxicity studies). For the remaining 16 substances [FL-no: 02.070, 02.075, 02.135, 02.167, 
06.136, 07.203, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] 
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the Panel concluded that they would present no safety concern at the estimated levels of intake based 
on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 9, REVISION 3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 9, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.070 
 
Cyclohexanol OH  
2138 
108-93-0 
Solid 
C6H12O 
100.16 
Slightly soluble 
Freely soluble 
158 
25 
MS 
95 % 
1.462-1.468 
0.942-0.948 
 
 
02.075 
 
neo-Dihydrocarveol 
OH
 
2296 
18675-34-8 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
Freely soluble 
107 (33 hPa) 
 
MS 
95 % 
1.476-1.482 
0.920-0.926 
 
Register name and CASrn to 
be changed to (1R,2S,5S)-
neo-Dihydrocarveol, 18675-
33-7 (EFFA, 2005l). 
02.135 
 
Cyclopentanol OH  
10193 
96-41-3 
Liquid 
C5H10O 
83.13 
Slightly soluble 
Freely soluble 
140 
 
MS 
95 % 
1.449-1.455 
0.945-0.951 
 
 
02.167 
 
Isodihydrocarveol 
OH
 
 
18675-35-9 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
Freely soluble 
90 (6.7 hPa) 
 
MS 
95 % 
1.475-1.481 
0.918-0.924 
 
Register name to be changed 
to (1R,2R,5S)-
Isodihydrocarveol. 
06.136 
 
6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one 
O
O
O
4285 
 
831213-72-0 
Liquid 
C13H22O3 
226.32 
Slightly soluble 
Soluble 
259 
 
IR NMR MS 
98.9 % 
1.4606-
1.4609 
1.017-1.021 
 
Mixture of isomers: (3S, 5R, 
6S,9R)-isomer: 65.6 % and 
(3S, 5S, 6S,9R)-isomer: 27.4 
%, mixture of other 
diastereomers: 5.86 % 
(Flavour Industry, 2006o). 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 9, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
07.203 
 
3,3,5-Trimethylcyclohexan-1-one O  
 
873-94-9 
Liquid 
C9H16O 
140.22 
Practically insoluble 
or insoluble 
Freely soluble 
189 
 
MS 
95 % 
1.442-1.448 
0.888-0.894 
 
Racemate (EFFA, 2010a). 
07.207 
 
Cyclotetradecanone 
CH2
CH2
CH2
CH2
CH2
CH2C
H2
H2C
H2C
H2C
H2C
H2C
H2C
O  
 
3603-99-4 
Solid 
C14H26O 
210.36 
Practically insoluble 
or insoluble 
Freely soluble 
159 (16 hPa) 
53 
NMR 
95 % 
n.a. 
n.a. 
 
 
09.154 
 
Menthyl valerate 
O
O
4156 
472 
89-47-4 
Liquid 
C15H28O2 
240.39 
Practically insoluble 
or insoluble 
Freely soluble 
261 
 
NMR 
95 % 
1.445-1.451 
0.903-0.909 
 
Register name to be changed 
to (1R,2S,5R)-5-methyl-2-
(1-methylethyl)cyclohexyl 
valerate (EFFA, 2010a). 
09.355 
 
neo-Dihydrocarvyl acetate 
O
O
 
10859 
56422-50-5 
Liquid 
C12H20O2 
196.29 
Practically insoluble 
or insoluble 
Freely soluble 
266 
 
MS 
95 % 
1.453-1.459 
0.925-0.931 
 
According to EFFA: 
Mixture of the two 
racematic forms (1S,2R,5R) 
and (1R,2S,5S ), which is 
specified by the name 
(EFFA, 2005l.).  
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 9, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.520 
 
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate 
O
O
O
3408 
10785 
24851-98-7 
Liquid 
C13H22O3 
226.32 
Slightly soluble 
Freely soluble 
111 (0.1 hPa) 
 
NMR 
98 % 
1.458-1.462 
0.997-1.006 
 
According to EFFA: 
Mixture of the four 
stereoisomeric forms (RR, 
RS, SR and SS) in relatively 
equal ratios (approximately 
25 % of each) (EFFA, 
2010a). 
09.618 
 
Menthyl formate 
OO
 
10751 
2230-90-2 
Liquid 
C11H20O2 
184.28 
Practically insoluble 
or insoluble 
Freely soluble 
95 (13 hPa) 
9 
MS 
95 % 
1.446-1.452 
0.933-0.939 
 
According to EFFA: 
Mixture of the two 
racematic forms (1S,2R,5S) 
and (1R,2S,5R ), which is 
specified by the name. 
09.619 
 
Menthyl hexanoate 
O
O
 
 
6070-16-2 
Liquid 
C16H30O2 
254.14 
Practically insoluble 
or insoluble 
Freely soluble 
153 (20 hPa) 
 
MS 
95 % 
1.445-1.451 
0.898-0.906 
 
Register name to be changed 
to (1R,2S,5R)-Menthyl 
hexanoate. 
09.621 
 
Menthyl salicylate 
OHO
O
 
 
89-46-3 
Liquid 
C17H24O3 
276.37 
Practically insoluble 
or insoluble 
Freely soluble 
175 (13 hPa) 
 
MS 
95 % 
1.509-1.515 
1.047-1.053 
 
Register name to be changed 
to (1R,2S,5R)-Menthyl 
salicylate. 
09.870 
 
Carvyl-3-methylbutyrate 
O
O
 
 
94386-39-7 
Liquid 
C15H24O2 
236.37 
Practically insoluble 
or insoluble 
Freely soluble 
343 
 
MS 
95 % 
1.462-1.468 
0.932-0.938 
 
According to EFFA: 
Mixture of the four 
stereoisomeric forms (RR, 
RS, SR and SS) in relatively 
equal ratios (approximately 
25 % of each) (EFFA, 
2010a). 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 9, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.929 
 
L-Monomenthyl glutarate 
O
O
O
OH
4006 
 
220621-22-7 
Liquid 
C15H26O4 
270 
Sparingly soluble 
Soluble 
390 (decomp) 
n.a. 
IR NMR 
95 % 
1.462-1.470 
1.026-1.036 
 
 
09.935 
 
Dimenthyl glutarate 
O
O
O
O
 
 
 
406179-71-3 
Solid 
C25H44O4 
408 
Insoluble 
Soluble 
 
48-50 
NMR MS 
98 % 
n.a. 
n.a. 
 
According to EFFA: 
Menthyl moiety mixture of 
the two racematic forms 
(1S,2R,5S) and (1R,2S,5R ), 
which is specified by the 
name. Since there are two 
menthyl moieties, three 
combinations exist,  
approximately 25 % +/+ 25 
% - /- and 50 % +/- (EFFA, 
2010a). 
 
09.949 
 
L-Menthyl (S)-3-hydroxybutyrate 
O
O OH
4308 
 
115869-76-6 
Liquid 
C14H26O3 
242.35 
Slightly soluble 
Soluble 
95-97 (0.7hPa) 
 
IR MS 
98 % 
1.454 - 1.464  
0.969 - 0.979 
 
Stereoisomeric composition 
of (S)-form : > 80 % ee and 
(R)-form < 20 %.ee 
(ee=enatiomeric excess). 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95%  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.070 
 
Cyclohexanol OH
 
3.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.075 
 
neo-Dihydrocarveol 
OH
2.4 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.135 
 
Cyclopentanol OH
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.167 
 
Isodihydrocarveol 
OH
2.4 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.154 
 
Menthyl valerate 
O
O
1.0 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.355 
 
neo-Dihydrocarvyl acetate 
O
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.618 
 
Menthyl formate 
OO
0.73 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.619 
 
Menthyl hexanoate 
O
O
0.37 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.621 
 
Menthyl salicylate 
OHO
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.870 
 
Carvyl-3-methylbutyrate 
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6) a) 
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.929 
 
L-Monomenthyl glutarate 
O
O
O
OH
110 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.935 
 
Dimenthyl glutarate 
O
O
O
O
30 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.949 
 
L-Menthyl (S)-3-
hydroxybutyrate 
O
O OH
37 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.203 
 
3,3,5-Trimethylcyclohexan-1-
one 
O 0.0085 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
07.207 
 
Cyclotetradecanone 
CH2
CH2
CH2
CH2
CH2
CH2C
H2
H2C
H2C
H2C
H2C
H2C
H2C
O 0.061 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
09.520 
 
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate 
O
O
O
770 
 
Class II 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL exists 
4) 6)  
06.136 
 
6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one 
O
O
O
12 
 
Class III 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Evaluated in FGE.212, genotoxic concern could be ruled out. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
Not in 
Register 
Methanol H
H
H
OH
Not evaluated as flavouring substance  Not a Register substance 
Not in 
Register 
3-Oxo-2-pentyl-1-cyclopentyl 
acetic acid 
O
OH
O
Not evaluated as flavouring substance  Not a Register substance. 
Not in 
Register 
(S)-3-Hydroxybutyric acid 
OH
HO
O
Not evaluated as flavouring substance  Not a Register substance. 
02.015 Menthol 
427 
OH
 
No safety concern a) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Not endogenous,  
A5: Adequate NOAEL exists 
NOAEL: 380 mg/kg bw/day. 
02.062 Carveol 
381 
OH
 
No safety concern a) 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
02.075 neo-Dihydrocarveol 
 
OH
 
 
Category B b) 
FGE.09 
Class I 
A3: Intake below threshold 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
07.176 trans-Menthone 
429 
O
(-)menthone shown
 
No safety concern a) 
 
 
Class II 
A3: Intake above threshold,  
A4: Not endogenous,  
A5: Adequate NOAEL exists 
 
08.001 Formic acid 
79 OHO  
Category 1 c) 
No safety concern d) 
Deleted b) 
 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.004 Lactic acid 
930 
OH
OH
O
 
No safety concern e) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.007 Valeric acid 
90 
OH
O
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.008 3-Methylbutyric acid 
259 
OH
O
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.009 Hexanoic acid 
93 
O
OH  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.082 Glutaric acid 
 
O
HO
O
OH  
 
 
 
FGE.10 
Class I 
A3: Intake below threshold 
 
Flavouring Group Evaluation 09, Revision 3
 
 
30 EFSA Journal 2011; 9(10):2396 
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.112 Salicylic acid 
958 
O
OH
OH
 
No safety concern e) 
 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2000a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 1999b). 
e) (JECFA, 2002b). 
ND)  Not detected. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.015 Menthol 
OH
 
63 
89-78-1 
427 
JECFA specification (JECFA, 
1998b) 
16000  
No safety concern a) 
Category A b) 
ADI: 0-4 (JECFA, 
2000a). 
02.061 Dihydrocarveol 
OH
2379 
2025 
619-01-2 
378 
JECFA specification (JECFA, 
1998b) 
0.37  
No safety concern a) 
Category B b) 
 
02.062 Carveol 
OH
2247 
2027 
99-48-9 
381 
JECFA specification (JECFA, 
1998b) 
9.5  
No safety concern a) 
Category B b) 
 
02.071 p-Menthan-2-ol 
OH
3562 
2228 
499-69-4 
376 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
Category B b) 
 
02.209 3,3,5-Trimethylcyclohexan-1-ol OH 3962 
 
116-02-9 
1099 
JECFA specification (JECFA, 
2002d) 
0.12  
No safety concern c) 
 
JECFA name: 3,3,5-
Trimethyl cyclohexanol. 
Flavouring Group Evaluation 09, Revision 3
 
 
32 EFSA Journal 2011; 9(10):2396 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.224 3-(1-Menthoxy)propane-1,2-diol 
O OH
OH
3784 
 
87061-04-9 
1408 
JECFA specification (JECFA, 
2005b) 
4.1  
No safety concern d) 
 
JECFA name: 3-L-
Menthoxypropane-1,2-
diol. 
02.246 p-Menthane-3,8-diol 
OH
OH
4053 
 
42822-86-6 
1416 
JECFA specification (JECFA, 
2005b)  
39  
No safety concern d) 
 
 
07.045 2,2,6-Trimethylcyclohexanone O 3473 
686 
2408-37-9 
1108 
JECFA specification (JECFA, 
2002d) 
2.1  
No safety concern c) 
Category B b) 
Stereoisomeric 
composition to be 
specified. 
07.092 p-Menthan-2-one 
O
3176 
11128 
499-70-7 
375 
JECFA specification (JECFA, 
1998b) 
0.012  
No safety concern a) 
 
 
07.095 2-(sec-Butyl)cyclohexanone O 3261 
11044 
14765-30-1 
1109 
JECFA specification (JECFA, 
2002d) 
5.1  
No safety concern c) 
 
 
07.110 Cycloheptadec-9-en-1-one O 3425 
11744 
542-46-1 
1401 
JECFA specification (JECFA, 
2005b) 
0.24  
No safety concern d) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
07.111 3-Methylcyclopentadecan-1-one O 3434 
11135 
541-91-3 
1402 
JECFA specification (JECFA, 
2005b) 
0.37  
No safety concern d) 
 
JECFA name: 3-Methyl-
1-cyclopentadecanone. 
07.128 Dihydrocarvone 
O
3565 
11703 
7764-50-3 
377 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
 
 
07.148 Cyclohexanone O 3909 
11047 
108-94-1 
1100 
JECFA specification (JECFA, 
2002d) 
0.12  
No safety concern c) 
 
 
07.149 Cyclopentanone O 3910 
11050 
120-92-3 
1101 
JECFA specification (JECFA, 
2002d) 
0.018  
No safety concern c) 
 
 
07.176 trans-Menthone 
O
(-)menthone shown
2667 
2035 
89-80-5 
429 
JECFA specification (JECFA, 
1998b) 
890  
No safety concern a) 
 
JECFA name: 
Menthone. 
CASrn in Register refers 
to cyclohexanone, 5-
methyl-2-(1-
methylethyl)-, (2R,5S)-
rel-. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
07.180 3-Methylcyclohexanone O 3947 
 
591-24-2 
1103 
JECFA specification (JECFA, 
2002d) 
0.12  
No safety concern c) 
 
 
09.016 Menthyl acetate 
OO
 
2668 
206 
29066-34-0 
431 
JECFA specification (JECFA, 
1998b) 
270  
No safety concern a) 
Category B b) 
JECFA evaluated 
menthyl acetate (CASrn 
16409-45-3 which does 
not specify isomer). 
CASrn in Register 
replaced by 89-48-5 
which refers to 
Cyclohexanol, 5-methyl-
2-(1-methylethyl)-, 
acetate, (1R,2S,5R) 
(SciFinder). 
09.027 Cyclohexyl acetate 
O
O 2349 
217 
622-45-7 
1093 
JECFA specification (JECFA, 
2002d) 
12  
No safety concern c) 
Category B b) 
 
09.140 Cyclohexyl propionate 
O
O 2354 
421 
6222-35-1 
1097 
JECFA specification (JECFA, 
2002d) 
0.012  
No safety concern c) 
Category B b) 
 
09.143 Carvyl propionate 
O
O
2251 
424 
97-45-0 
383 
JECFA specification (JECFA, 
2000d) 
ND  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.160 Cyclohexyl formate 
O
O 2353 
498 
4351-54-6 
1095 
JECFA specification (JECFA, 
2002d) 
0.012  
No safety concern c) 
Category B b) 
 
09.215 Carvyl acetate 
OO
2250 
2063 
97-42-7 
382 
JECFA specification (JECFA, 
1998b) 
4.0  
No safety concern a) 
Category B b) 
 
09.216 Dihydrocarvyl acetate 
O
O
2380 
2064 
20777-49-5 
379 
JECFA specification (JECFA, 
1998b) 
9.7  
No safety concern a) 
Category B b) 
 
09.230 Cyclohexyl butyrate 
O
O 2351 
2082 
1551-44-6 
1094 
JECFA specification (JECFA, 
2002d) 
0.89  
No safety concern c) 
Category B b) 
 
09.464 Cyclohexyl isovalerate 
O
O 2355 
459 
7774-44-9 
1096 
JECFA specification (JECFA, 
2002d) 
0.28  
No safety concern c) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.521 Methyl 3-oxo-2-pent-2-enyl-1-
cyclopentylacetate 
O
O
O
3410 
10821 
39924-52-2 
1400 
JECFA specification (JECFA, 
2005b) 
26  
No safety concern d) 
 
JECFA evaluated 
methyl jasmonate 
(CASrn 1211-29-6). 
(R)- or (S)- nor (E)- or 
(Z)- not specified by 
Register CASrn. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2000a). 
b) (CoE, 1992). 
c) (JECFA, 2002c). 
d) (JECFA, 2005c). 
ND) No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
The use levels from food category 5 “Confectionery” have been inserted as default values for food category 
14.2 “Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 
2007a). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry (EFFA, 2003a; EFFA, 2007a; Flavour 
Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; Flavour Industry, 2010f; Flavour 
Industry, 2010k) for 16 of the 17 candidate substances in the present flavouring group (Table II.1.2). 
Table II.1.2.Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.09Rev3 (EFFA, 2003a; 
EFFA, 2007a; Flavour Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; Flavour Industry, 2010f; 
Flavour Industry, 2010k) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.07
0 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.07
5 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.13
5 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.16
7 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
06.13
6 
0,000
1 
0,000
5 
0,000
1 
0,000
1 
0,000
1 
0,000
8 
- 
- 
- 
- 
0,00
1 
0,00
5 
0,000
1 
0,000
5 
0,000
1 
0,000
5 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,000
1 
0,000
5 
0,000
1 
0,000
5 
0,000
1 
0,000
8 
- 
- 
0,000
1 
0,000
5 
07.20
3 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
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Table II.1.2.Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.09Rev3 (EFFA, 2003a; 
EFFA, 2007a; Flavour Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; Flavour Industry, 2010f; 
Flavour Industry, 2010k) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
07.20
7 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.15
4 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.35
5 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
09.52
0 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.61
8 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.61
9 
7 
35 
5 
25 
1 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.62
1 
0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
09.87
0 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
09.93
5 
1 
15 
1 
15 
10 
150 
1 
15 
1 
15 
100 
1500 
- 
- 
10 
150 
1 
15 
1 
15 
- 
- 
- 
- 
1 
15 
- 
- 
100 
1500 
100 
1500 
1 
15 
1 
15 
09.94
9 
30 
150 
- 
- 
10 
50 
20 
100 
- 
- 
50 
200 
5 
20 
20 
100 
- 
- 
- 
- 
- 
- 
- 
- 
10 
30 
- 
- 
10 
50 
10 
50 
30 
150 
10 
30 
 
The candidate substance [FL-no. 09.949] is also anticipated to be used in chewing gum, which is not covered 
by any of the above food categories. The normal/maximum use levels for chewing gum are reported to be 
500/1000 mg/kg for [FL-no: 09.949]. Under the assumptions that all of the flavouring substance is released 
from the chewing gum and that the intake estimate is 2 g chewing gum/day, the calculation of the mTAMDI 
of the candidate substance based on the 16 food categories and the use of chewing gum sum up to 10600 
μg/person/day. This figure is presented in table II.2.3 and 6.1. 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up. 
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
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• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the 17 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2003a; EFFA, 2007a; Flavour 
Industry, 2004h; Flavour Industry, 2006c; Flavour Industry, 2006o; Flavour Industry, 2010f; Flavour 
Industry, 2010k). The mTAMDI values are only given for highest reported normal use levels (see Table 
II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.070 Cyclohexanol 1600 Class I 1800 
02.075 neo-Dihydrocarveol 1600 Class I 1800 
02.135 Cyclopentanol 1600 Class I 1800 
02.167 Isodihydrocarveol 1600 Class I 1800 
09.154 Menthyl valerate 3900 Class I 1800 
09.355 neo-Dihydrocarvyl acetate 1600 Class I 1800 
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09.618 Menthyl formate 3900 Class I 1800 
09.619 Menthyl hexanoate 3900 Class I 1800 
09.621 Menthyl salicylate 420 Class I 1800 
09.870 Carvyl-3-methylbutyrate 1000 Class I 1800 
09.929 L-Monomenthyl glutarate  Class I 1800 
09.935 Dimenthyl glutarate 38000 Class I 1800 
09.949 L-Menthyl (S)-3-hydroxybutyrate 10600 Class I 1800 
07.203 3,3,5-Trimethylcyclohexan-1-one 1600 Class II 540 
07.207 Cyclotetradecanone 3900 Class II 540 
09.520 Methyl 3-oxo-2-pentyl-1-cyclopentylacetate 3900 Class II 540 
06.136 6-Isopropyl-3,9-dimethyl-1,4-dioxyspiro[4.5]decan-2-one 0.075 Class III 90 
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ANNEX III: METABOLISM 
III.1. Absorption, Distribution and Elimination 
The candidate substances of secondary alicyclic saturated and unsaturated alcohols, ketones and esters of the 
present flavouring group evaluation are expected to be rapidly absorbed from the gastrointestinal tract. 
Supporting substances evaluated by the JECFA sustain this view (JECFA, 1999a; JECFA, 2003a). 
III.2. Biotransformation 
The candidate substances are expected to be metabolised through several alternative metabolic pathways. 
Depending on their chemical structure, the possible metabolic reactions are the following: 
III.2.1  Ester hydrolysis 
III.2.2  Reduction of ketone groups and oxidation of alcohol groups 
III.2.3  Oxidation of alkyl groups on alkyl substituted alicyclic ketones and alcohols 
III.2.4  Metabolism to glucuronides 
III.2.5  Metabolism to sulphates 
No information is available on the toxicokinetics of the candidate substance cyclotetradecanone [FL-no: 
07.207] or any related supporting substances in the present FGE. 
III.2.1. Ester hydrolysis  
The esters included in this FGE are expected to be hydrolysed enzymatically to carboxylic acids and alcohols 
via carboxylesterases found in most tissues throughout the body, the most important of which are the beta-
esterases (Heymann, 1980). For the one hemiketal ester [FL-no: 06.136] hydrolysis to the corresponding 
cyclic ketone, p-menthan-3-one [FL-no: 07.059] and lactic acid [FL-no: 08.004] is expected.  
The supporting substances, menthyl acetate [FL-no: 09.016] and dihydrocarvyl acetate [FL-no: 09.216] were 
previously evaluated by the JECFA (JECFA, 1999a), but no metabolism studies were available for these 
supporting substances, structurally related to the candidate substances neo-dihydrocarvyl acetate, menthyl 
formate and menthyl hexanoate [FL-no: 09.355, 09.618 and 09.619]. The JECFA evaluation was based on a 
study demonstrating about 75 % and 85 % hydrolysis of 1-menthol propylene glycol carbonate and 1-
menthol ethylene glycol carbonate, respectively, after four hours in liver homogenate. Less than 20 % of 
these two substances were hydrolysed in gastric juice and intestinal fluid (Emberger, 1994a; Emberger, 
1994b). More than 80 % of a radioactively labelled mandelic acid of 3,3,5-trimethylcyclohexanol, a 
cyclohexyl ester structurally related to the candidate substance menthyl salicylate [FL-no: 09.621], was 
hydrolysed after 15 minutes of incubation with rat hepatic microsomes (White et al., 1990).  
Based on these data, it is anticipated that candidate esters and the one hemiketal ester [FL-no: 06.136, 
09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949], after intestinal 
absorption are hydrolysed to the corresponding alcohols/ketone and their corresponding carboxylic acids (see 
Table 2b). The simple mono- and di-carboxylic acids [FL-no: 08.001, 08.002, 08.004, 08.007, 08.008, 
08.009 and 08.082] are expected to be completely metabolised through common routes of 
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biotransformations. For salicylic acid [FL-no: 08.112] and for 3-oxo-2-pentyl-1-cyclopentyl acetic acid 
(formed from [FL-no: 09.520]) the acids are anticipated to be conjugated and excreted with the urine.  
III.2.2. Reduction of ketone groups and oxidation of alcohol groups 
Three of the candidate substances [FL-no: 07.207, 07.203 and 09.520] contain a ketone group, which may be 
metabolically reduced to a hydroxyl group. This may also be expected for the hemiketal ester [FL-no: 
06.136] after hydrolysis to ketone. 
Metabolism of the supporting substance carveol, the hydrolysis product of carvyl-3-methylbutyrate [Fl-no: 
09.870], was studied in vitro. (+)-Carveol and (+)-carvone were incubated with liver microsomes from dogs, 
rabbits, guinea pigs, mice, rats, monkeys and humans. (+)-Carveol was oxidized to (+)-carvone by liver 
microsomes of dogs, rabbits and guinea pigs, but not by those of humans, monkeys, rats and mice. On the 
other hand the (+)-carvone was reduced to (+)-carveol by liver microsomes of all animals examined. These 
results suggest a species specific metabolism of (+)-carveol, and shows that carveol is not converted to 
carvone in the liver of humans (Shimada et al., 2002). 
In vivo metabolism of l-menthol was studied in adult male rats by giving the rats 800 mg/kg bw l-menthol 
solved in 1 % methyl cellulose solution by gavage every day for 20 days. Control rats were given vehicle 
only. The following metabolites of l-menthol were found in the urine; p-menthane-3,8-diol, p-menthane-3,9-
diol, 3,8-oxy-p-menthane-7-carboxylic acid and 3,8-dihydroxy-p-menthane-7-carboxylic acid. The main 
urinary metabolites were p-menthane-3,9-diol and 3,8-dihydroxy-p-menthane-7-carboxylic acid. Menthone 
was not detected (Madyastha and Srivatsan, 1988a). 
III.2.3. Oxidation of alkyl groups on alkyl substituted alicyclic ketones and alcohols 
Oxidation of alkyl groups have been observed for menthol and for the hydrolysis product of the candidate 
esters neo-dihydrocarvyl acetate [FL-no: 09.355] and menthyl formate [FL-no: 09.618], and for the 
candidate substance 3,3,5-trimethylcyclohexan-1-one [FL-no: 07.203] (Truhaut et al., 1970; Yamaguchi et 
al., 1994). 
III.2.4. Metabolism to glucuronides  
The hydrolysis product menthol as such or after the oxidation of the alkyl ring substituents is mainly 
conjugated with glucuronic acid and excreted via the bile in rats. Low levels of oxidation products were 
found in the urine, but no unchanged menthol was detected in the urine, faeces or bile after oral 
administration of radioactive labelled menthol (Yamaguchi et al., 1994).  
The candidate substances isodihydrocarveol and neo-dihydrocarveol [FL-no: 02.167 and 02.075], are also 
anticipated to be conjugated with glucuronic acid, since dihydrocarveol after application by gavage to rabbits 
was found in the urine as the glucuronide (Hämäläinen, 1912; JECFA, 1999a). However, dihydrocarveol was 
also found to be excreted unchanged (Fischer and Bielig, 1940; JECFA, 1999a). The glucuronic acid 
conjugate of dihydrocarveol has been detected in the urine of rabbits (Hämäläinen, 1912). In rabbits, carvone 
is reduced to yield carveol, which then is converted to the glucuronic acid conjugate and excreted in the 
urine (Fischer and Bielig, 1940). Carveol, the hydrolysis product of carvyl-3-methylbutyrate [FL-no: 09.870] 
is therefore anticipated to be conjugated with glucuronic acid and excreted in the urine 
Salicylic acid (resulting from hydrolysis of menthyl salicylate [FL-no: 09.621]) is either excreted unchanged, 
or as salicyluric acid and salicylic glucuronide (Vree et al., 1994). 
The candidate alicyclic ketone (3,3,5- trimethylcyclohexan-1-one [FL-no: 07.203]) is anticipated to be 
reduced to the corresponding secondary alcohol. This secondary alcohol and the candidate secondary 
alcohols cyclopentanol and cyclohexanol [FL-no: 02.135 and 02.070] are mainly excreted as conjugates with 
glucuronic acid. Studies in rabbits with the supporting substance cyclohexanone [FL-no: 07.148] and with 
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cyclopentanone and cycloheptanone show that 50 - 70 % of these substances are reduced to the 
corresponding alcohols (the candidate substances cyclohexanol [FL-no: 02.070] and cyclopentanol [FL-no: 
02.135] and cycloheptanol), which are conjugated with glucuronic acid and excreted (Elliott et al., 1959; 
James and Waring, 1971). Workers employed in a shoe factory were exposed to small amounts of 
cyclohexane in the air. Cyclohexanol and cyclohexanone were found in the urine of these workers, indicating 
that the same metabolic pathways are also found in humans (Governa et al., 1987). A recent study in humans 
shows that the main metabolite in urine after cyclohexanone or cyclohexanol exposure is not cyclohexanol-
glucuronide as in rabbit and rats, but 1,2-cyclohexanediol-glucuronide (Mráz et al., 1994; Mráz et al., 1998).  
When the candidate substance 3,3,5-trimethylcyclohexan-1-one [FL-no: 07.203], was given to rats and 
rabbits glucuronides of 3,5,5-trimethyl cyclohexanol were detected in the urine (Truhaut et al., 1979). 
III.2.5. Metabolism to sulphates 
A small fraction of the two candidate substances, cyclopentanol and cyclohexanol [FL-no: 02.135 and 
02.070], is anticipated to be conjugated with sulphate and excreted in the urine. This is based on studies on 
the structurally related substances cyclopentanone, cyclohexanone and cycloheptanone, which were given by 
gavage to rabbits (1.7 - 2.3 mmol/kg) and rats (1.8 - 2.5 mmol/kg), and 1 - 3 % of the dose was found in the 
urine as sulphate conjugates (James and Waring, 1971). 
III.3. Summary and Conclusions 
The 10 esters [FL-no: 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] 
included in this FGE are expected to be hydrolysed to the corresponding carboxylic acids and alcohols, 
based on the evaluation of supporting substances (Heymann, 1980; Anders, 1989; Emberger, 1994a; 
Emberger, 1994b; White et al., 1990). The resulting carboxylic acids are either metabolised through common 
physiological pathways like beta-oxidation and the citric acid cycle or excreted in conjugation with 
glucuronide (Keefer et al., 1987; Vree et al., 1994). 
The one hemiketal ester [FL-no: 06.136] is expected to be hydrolysed to the corresponding cyclic ketone, p-
menthan-3-one [FL-no: 07.176] and lactic acid [FL-no: 08.004]. 
One of the main pathways for the candidate alcohols and the ketones (after reduction) [FL-no: 02.070, 
02.075, 02.135, 02.167, 07.203 and 09.520] is conjugation with glucuronic acid followed by excretion. 
Menthol, carveol and dihydrocarveol, hydrolysis products of [FL-no: 06.136, 09.154, 09.355, 09.618, 
09.619, 09.621, 09.870, 09.929, 09.935 and 09.949] are also metabolised via this pathway. Neither menthol 
nor carveol is anticipated to be oxidised to the corresponding ketone. 
Additional pathways involved in the metabolism of the candidate substances are reduction of ketone groups, 
oxidation of alkyl groups of alkyl substituted alicyclic ketones followed by conjugation with glucuronic acid 
and/or sulphates resulting in excretion. Thus, it may be anticipated that these 16 substances will be 
metabolised to innocuous products. 
No information is available on toxicokinetics (including metabolism) of cyclotetradecanone [FL-no: 07.207] 
or on structurally related substances. Cyclotetradecanone [FL-no: 07.207] cannot be assumed to be 
metabolised to innocuous products. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for five candidate substances of the present FGE and for ten supporting substances evaluated by the JECFA at the 51st, 
59th and 63rd meetings. The supporting substances are listed in brackets. 
Table IV.1: ACUTE TOXICITY 
Chemical Name  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Menthol [02.015]) Mouse  M  Gavage  2652  (Food and Drug Research Laboratories, Inc., 
1975a)  
 
Mouse  M  Gavage  4384  (Food and Drug Research Laboratories, Inc., 
1975a) 
 
Mouse  NR  Gavage  3100  (Wokes, 1932)  
Rat  M, F  Gavage  3180  (Jenner et al., 1964)  
Rat  M  Gavage  940  (Food and Drug Research Laboratories, Inc., 
1975a) 
 
(trans-Menthone [07.176]) Rat  M, F  Oral  1600 – 1950    (Igimi and Ide, 1974; Levenstein, 1973c) Testmaterial = racemic menthone 
(Menthyl acetate [09.016]) Rat  M, F  Gavage  > 7000  (Levenstein, 1973d) Testmaterial = racemic menthyl acetate 
Rat  M, F  Oral  > 5000  (Shelanski, 1972a) Testmaterial = l-menthyl acetate 
(Dihydrocarveol [02.061]) Rat  NR  Oral  > 5000  (Moreno, 1977k)  
(Dihydrocarvyl acetate [09.216]) Rat  NR  Oral  > 5000  (Moreno, 1980f)  
neo-Dihydrocarvyl acetate [09.355] Rat  NR  Oral  > 5000  (Moreno, 1980f)  
Cyclopentanol [02.135] Rat  NR  Gavage  < 625  (Myers et al., 1980)  
(3,5,5-Trimethyl cyclohexanol [02.209]) Rat  M, F  Oral  3250  (Smyth and Carpenter, 1948)  
(Cyclohexanone [07.148]) Rat  M, F  Oral  1705  (Kohli et al., 1967)  
Rat  M, F  Oral  1840  (Deichmann and LeBlanc, 1943)  
Rat  M, F  Oral  1620  (Smyth et al., 1969a)  
Rat  M, F  Oral  1800  (Gupta et al., 1979)  
Mouse  M, F  Oral  2070  (Gupta et al., 1979)  
Rabbit  M  Gavage  1600  (Treon et al., 1943)  
Rabbit  M  IP 1540  (Gupta et al., 1979)  
Guinea pig M  IP 930  (Price, 1951)  
Cyclohexanol [02.070] Rat  M  Gavage  1750  (Miller and Sherman, 1965)  
Rat  NR  Oral  1550  (Birch, 1978a)  
Rat  NR  Oral  20601 (Smyth et al., 1946c)  
Rat  NR  Oral  2060  (Bär and Griepentrog, 1967)  
Rat  M, F  Oral  1120  (Birch et al., 1981)  
Rabbit  NR  Gavage  2200 – 26002 (Treon et al., 1943)  
(3-Methylcyclopentadecan-1-one [07.111]) Dog M, F  > 2000 (You et al., 1997)  
Rat M, F  > 5000 (Oh et al., 1997)  
6-Isopropyl-3,9-dimethyl-1,4-dioxyspiro[4.5]decan-2-
one [06.136] 
Rat NR Oral >2000 (Flavour Industry, 2006c)  
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate [09.520] Rat NR Oral > 2000 (Flavour Industry, 2006c)  
(Carveol [02.062]) Rat NR Oral 3000 (Keating, 1972a)  
(Carvyl acetate [09.215]) Rat NR Oral > 5000 (Levenstein, 1976c)  
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NR: Not reported, M: Male, F: Female. 
1 Administered as 10 % solution in Tergitol 7. 
2 Minimum lethal dose. 
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Subacute / subchronic / chronic toxicity data are available two candidate substance of the present flavouring group and for five supporting substances 
evaluated at the 51st, 59th and 63rd JECFA meetings. The supporting substances are listed in brackets. 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name  Species; Sex 
No./Group 
Route  Dose levels Duration   NOAEL 
(mg/kg/day) 
Reference  Comments 
(Menthol [02.015]) Mouse; M, F 
2/50 
Diet  2000, 4000 ppm 103 weeks  6001  (National Cancer Institute, 
1979) 
Good quality 
Mouse; F  
2/30 
Intraperitoneal injection 
(IP) 
500 and 2000 mg/kg 
3 times week 
24 weeks  A NOAEL was not determined (Stoner et al., 1973) Good quality 
Rat; M, F 
3/20 
Gavage  0, 200, 400 and 800 
mg/kg bw day 
28 days  < 2002  (Thorup et al., 1983a) Relative good quality 
Rat; M, F  
2/80 
Diet  100 and 200 
mg/kg bw 
5.5 weeks  2001  (Herken, 1961) Limited information 
Rat; M, F 
2/50   
Diet  3750 and 7500 
ppm 
103 weeks  3751  (National Cancer Institute, 
1979) 
Good quality 
(trans-Menthone [07.176])  Rat; M, F 
3/20 
Gavage  200, 400 and 800 
mg/kg bw day 
28 days  400  (Madsen et al., 1986) Good quality 
Mouse; F  
2/30 
IP  1900 and 4750 mg/kg 
3 times week 
24 weeks  A NOAEL was not determined2  (Stoner et al., 1973) Good quality 
(Cyclohexanone [07.148]) Mouse; M, F 
7/20 
Drinking Water 400 - 47000 ppm 13 weeks  M: approx. 3300, F: approx. 6500  (Lijinsky and Kovatch, 
1986) 
Good quality 
Rat; M, F     
7/10 
Drinking water 190 - 6500 ppm 25 weeks  Approx. 330 (Lijinsky and Kovatch, 
1986) 
Good quality 
Mouse; M, F 
3/84-104 
Drinking water 6500, 13000 and 25000 (F) ppm 2 years  Approx. 1600 (Lijinsky and Kovatch, 
1986) 
Good quality 
Rat; M, F 
2/104 
Drinking water 3300 and 6500 ppm 2 years  Approx. 330 (Lijinsky and Kovatch, 
1986) 
Good quality 
Rat  
1/7 
IP 200 mg/kg bw (twice a day) 5 
days/week 
13 weeks  A NOAEL was not determied1 (Perbellini et al., 1981) Only neurotoxicity 
was checked. Limited 
experimental design 
Cyclohexanol [02.070] Rats  
1/7 
IP 200 mg/kg bw (twice a day) 5 
days/week  
3 weeks (twice a 
day) plus 3 weeks 
(once a day)  
A NOAEL was not determied1 (Perbellini et al., 1981) Limited experimental 
design 
Rat; M  
1/6 
Gavage  455 mg/kg day 7 days  4551  (Lake et al., 1982) Limited quality 
Rat; M  
1/NR 
Drinking water 10 ppm 30 days  11 (Messiha and Lox, 1985) Limited quality 
(2-sec-Butylcyclohexanone 
[07.095]) 
Rat 
3/NR 
Diet  91 370 (Hummler, 1969) Study  not available 
(3-Methylcyclopentadecan-1-one 
[07.111]) 
Rat, M, F 
3/20 
Gavage  30 10003 (Oh et al., 1997)  
Dog, M, F 
3/6 
Gavaga  28 203 (You et al., 1997)  
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [09.520] 
Rat M, F 
10/8 
Diet 0, 10, 50 or 100 mg/kg bw day 90 100 (Kelly and Bolte, 2000)  
NR: Not reported 
M: Male, F: Female 
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1 The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
2 The test substance was administered 3 times per week for 8 weeks; animals were observed for an additional 16 weeks. 
3 Study was performed with either a single dose or multiple doses that produced no advere effect. The value is therefore not a true NOEL, but is the highest dose tested that produced no adverse effects. The actual NOEL may be higher.
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Developmental and reproductive toxicity data are only available for one candidate substance of the present FGE and for one supporting substance evaluated at 
the 51st JECFA meeting. Supporting substance is listed in brackets. 
Table IV.3: Developmental and Reproductive Toxicity Studies 
Chemical Name  Study type 
Duration 
Species/Sex  
No/group 
Route  Dose  levels (mg/kg/day) NOAEL 
(mg/kg/day) Including 
information on possible 
maternal toxicity 
Reference  
(Menthol [02.015]) Teratology 
Gestation days 6-15 
Mouse; F 
22 
Gavage  0, 1.85, 8.59, 39.9, 185 1851  (Food and Drug Research Laboratories, Inc., 1973) 
Teratology 
Gestation days 6-15 
Rat; F  
22-23 
Gavage  0, 2.18, 10.15, 47.05, 218 2181  (Food and Drug Research Laboratories, Inc., 1973) 
Teratology 
Gestation days 6-15 
Hamster; F 
20-22 
Gavage  0, 4.05, 21.15, 98.2, 405 4051  (Food and Drug Research Laboratories, Inc., 1973) 
Teratology 
Gestation days 6-18 
Rabbit; F 
9-11 
Gavage  0, 4.25, 19.75, 91.7, 425 4251  (Food and Drug Research Laboratories, Inc., 1973) 
Cyclohexanol [02.070] Reproductive 
NR2 
Mouse; M, F 
NR 
Diet  ca. 1500 (1 %) < 1500 (< 1 %) (Gondry, 1972) 
NR: Not reported. 
M: Male, F: Female. 
1 The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
2 Animals were exposed during gestation, lactation and weaming over multiple generations. Total length of exposure not reported. 
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In vitro mutagenicity/genotoxicity data are available for three candidate substances of the present flavouring group evaluation and for nine supporting 
substances evaluated at the 51st, 59th and 63rd JECFA meetings and one structurally related substance evaluated by JECFA at the 69th meeting. Supporting 
substances and the structurally related substance are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test system Test Object  Concentration  Result  Reference  Comments 
(Menthol [02.015]) Ames test  S. typhimurium TA92, TA94, TA98, TA100, 
TA1535, TA1537 
0, and 6 concentrations up 
to 5000 µg/plate  
Negative1  (Ishidate et al., 1984) d,l-Menthol was used. The study is considered valid.   
Ames test (preincubation method) S. typhimurium TA97, TA98, TA100, TA1535 3 - 666 µg/plate  Negative1 (Zeiger et al., 1988) d,l-Menthol was used. The study is considered valid.  
Ames test  S. typhimurium TA98, TA100, TA2637 0, 5 - 500 µg/plate  Negative1  (Nohmi et al., 1985) d,l-menthol was tested. The highest concentrations 
were cytotoxic. The study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA2637 0, 20 - 500 µg/plate  Negative1  (Nohmi et al., 1985) l-menthol was tested. The highest concentrations 
were cytotoxic. The study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 6.4, 32, 160, and 800 
µg/plate  
Negative1  (Andersen and Jensen, 
1984b) 
No indication of which enantiomer was used. In the 
absence of metabolic activation, the highest 
concentration was cytotoxic. The study is considered 
valid. 
Ames test  E. coli WP2 uvrA (Trp-) 100 - 800 µg/plate  Negative  (Yoo, 1986) l-Menthol was used. The article is not in English. 
The validity of the study cannot be evaluated. It is 
unclear whether metabolic activation or a control 
group was used. 
Ames test  S. typhimurium TA97A, TA98, TA100, TA102 0, 5 - 800 µg/plate  Negative1  (Gomes-Carneiro et al., 
1998) 
(-)-Menthol was used. The range of concentrations 
tested varied between the different strains. 
Cytotoxicity was observed with the highest 
concentrations tested with TA97A and, in the 
presence of metabolic activation, the highest 
concentration tested with TA102. The study is 
considered valid. 
Rec assay  B. subtilis H17, M45 Up to 10000 µg/disk  Positive (Yoo, 1986) l-Menthol was used. Inhibition zone for rec- and rec+ 
was 42 and 23 mm, respectively. The article is not in 
English. It is not clear from the study whether 
metabolic activation, or a control group was used. 
The validity of this study cannot be assessed. The 
method (rec-assay) has poor predictive value. 
Rec assay  B. subtilis H17, M45 20 µg/disk  Negative (Oda et al., 1979) l-Menthol was used. The article is not in English. 
Only one concentration level is mentioned at a table. 
No data on metabolic activation or control group. 
The validity of this study cannot be evaluated. The 
method (rec-assay) has poor predictive value. 
Alkaline elution assay Rat hepatocytes  0, 0.1 - 1.3 mM  (203.2 
µg/ml4) 
Negative (Storer et al., 1996) The experiment employed d-Menthol. An increase in 
DNA breaks was only observed at concentrations 
associated with cytotoxicity. The authors concluded 
that this was a false-positive result. The study is 
considered valid.                          
Sister chromatid exchange Chinese hamster ovary cells 5 – 50 amd 0, 2 – 25 µg/ml3
0, 16 - 167 µg/ml 2 
Negative1  (Ivett et al., 1989) d,l-Mentol was used. The compound was tested up to 
toxic or nearly toxic concentration levels. The study 
is considered valid. 
Sister chromatid exchange Human lymphocytes 0, 0.1, 1, 10 mM  (1563 Negative1  (Murthy et al., 1991) The study is considered valid. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test system Test Object  Concentration  Result  Reference  Comments 
µg/ml4) 
Cytogenetic assay Human embryonic lung cells 0, 0.1, 1, 10 µg/ml  Negative  (Food and Drug 
Research Laboratories, 
Inc., 1975a) 
The report does not  mention exogenous metabolic 
activation. The study is considered valid. 
Chromosome aberration Chinese hamster fibroblasts 0 and three concentrations 
up to 200 µg/ml  
Negative3  (Ishidate et al., 1984) The maximum concentration (cytotoxic) was selected 
by a preliminary test. The study is considered valid. 
Chromosome aberration Chinese hamster ovary cells 0, 50 - 250 µg/ml  Negative1  (Ivett et al., 1989) d,l-Mentol was used. The compound was tested up to 
toxic or nearly toxic concentration levels. The study 
is considered valid. 
Chromosome aberration Human lymphocytes 0, 0.1, 1, 10 mM (1563 
µg/ml4)  
Negative1  (Murthy et al., 1991) The study is considered valid. 
Gene mutation assay Mouse lymphoma L5178Y TK+/-cells 0, 12.5 - 200 µg/ml  Negative1  (Myhr and Caspary, 
1991) 
d,l-Menthol was used. The maximum concentration 
was selected by a preliminary test The study is 
considered valid.                                         
(trans-Menthone 
[07.176]) 
Ames test  S. typhimurium TA97, TA98, TA100, TA1535, 
TA1537 
0, 6.4 - 800 µg/plate  Positive1  
 
(Andersen and Jensen, 
1984b) 
Concentrations were selected based on preliminary 
experiments. In absence of metabolic activation, 
menthone was mutagenic only to strain TA1537 at 
6.4 and 32 μg/ml (slightly less than 2-fold increase in 
mutation frequency), but not at higher (toxic) 
concentrations. Also in absence of metabolic 
activation, there was a concentration dependent 
increase in number of TA97 strain revertants (up to 
4-fold increase at 600 μg/l). It was stated that 
metabolic activation did not enhance the 
mutagenicity of menthone. The study is considered 
valid. 
Cyclopentanol 
[02.135]  
Modified Ames test S. typhimurium G46, TA98, TA100, TA1535, 
C3076, TA1537, D3052, TA1538  
E. coli WP2, WP2 uvrA- 
0, 0.1 - 1000 µg/ml  Negative1  (McMahon et al., 1979) The study was performed with agar plates containing 
the following concentration gradients: 0.1 - 1, 1 - 10, 
10 - 100, and 100 - 1000 μg/ml. The study is 
considered valid, although tabulated data on 
cyclopentanol were not presented. 
(Cyclohexanone 
[07.148]) 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 33-10000 µg/plate  Negative1  (Haworth et al., 1983) The highest level tested was the highest of 
either10000 μg/plate, limit of solubility or maximal 
non-toxic concentration. The test was run twice. 
Both rat and hamster liver S9 were used. The test is 
considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 3 µmol/plate  Negative1  (Florin et al., 1980) A preliminary assay was performed with the four 
strains using only one concentration level (3 
μmol/plate). This assay gave uncertain results. In 
addition, strains TA98 and TA100 were exposed to 
0.03 - 30 μmol/plate. The validity of the study cannot 
be evaluated. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 NR Positive (Massoud et al., 1980) Only an abstract is available. No reporting with 
respect to metabolic activation. The substance was 
also tested with Bacillus subtilis. With this specie, 
toxicity was found as well as a positive response. 
The validity of the study cannot be evaluated because 
of lack of experimental information. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test system Test Object  Concentration  Result  Reference  Comments 
Cytogenetic assay Human leukocytes 0.1 – 10 mM  Inconclusive
3  
(Collin, 1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose response relationship. There was no 
information with respect to cytotoxicity or presence 
of a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate. 
Chromosomal aberration Human lymphocytes 0, 0.005 -  0.1 µg/ml Positive  (Dyshlovoi et al., 1981) Article is not in English. Only an abstract available 
in English. The validity of the study cannot be 
evaluated.             
Gene mutation (HPRT) Chinese hamster ovary cells 0, 7.5 µg/ml  Negative1  (Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated.  
Chromosomal aberration Chinese hamster ovary cells 0, 7.5 µg/ml  Negative1  (Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated.  
Sister chromatic exchange Chinese hamster ovary cells 0, 7.5 µg/ml  Positive3  
Negative2 
(Aaron et al., 1985) Only an abstract is available with limited 
experimental information. The validity of the study 
cannot be evaluated. 
Cyclohexanol 
[02.070] 
Ames test  S. typhimurium TA98, TA1535, TA1537, TA1538 500 - 10000 µg/plate3 
500 - 15000 µg/plate2 
Negative1  (Barsky, 1976) The highest concentrations showed cytotoxicity. The 
study is considered valid. 
Ames test  S. typhimurium TA98, TA100, TA1535, TA1537 0, 10 – 3333 µg/plate Negative1  (Haworth et al., 1983) The highest level tested was the highest of either 
10000 μg/plate, limit of solubility or maximal non-
toxic concentration. Both rat and hamster liver S9 
were used. The test was run twice. The study is 
considered valid. 
Chromosomal aberration Human leukocytes  0.1 - 10 mM  Inconclusive
3 
(Collin, 1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose response relationship. There was no 
information with respect to cytotoxicity or presence 
of a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate. 
(Cyclohexyl acetate 
[09.027]) 
DNA damage B. subtilis H17(rec+), M45 (rec–) 19 mg/disc Negative1 (Yoo, 1986)  
(Cyclohexyl butyrate 
[09.230]) 
DNA damage B. subtilis H17(rec+), M45 (rec-) 19 mg/plate Negative1 (Oda et al., 1979)  
(Cycopentanone 
[07.149]) 
Reverse mutation S. typhimurium TA98, TA100, TA1535, TA1537 2.5 - 2500 mg/plate Negative1 (Florin et al., 1980)  
(2,2,6-Trimethyl 
cyclo-hexanone 
[07.045]) 
Reverse mutation S. typhimurium TA98, TA100, TA1535, TA1537 4.2 - 3600 mg/plate Negative1 (Florin et al., 1980)  
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
[09.520] 
Reverse mutation S. typhimurium TA98, TA100, TA102, 
TA1535,TA1537 
5 mg/plate Negative1 (Thompson, 2000) Valid study in compliance with the OECD Guideline 
-471. 
Reverse mutation E. coli WP2 uvrA 5 mg/plate Negative1 (Wagner and Klug, 
2000) 
Valid study in compliance with the OECD Guideline 
-471. 
Flavouring Group Evaluation 09, Revision 3
 
 
54 EFSA Journal 2011; 9(10):2396 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test system Test Object  Concentration  Result  Reference  Comments 
Forward mutation Test Mouse lymphoma cells L5178y 200 & 300µg/L 
300 µg/L 
Positive3
Positive3 
(Ross and Harris, 
1979b) 
Pre-GLP study - not possible to assess the reliability 
of these studies. 
Forward mutation Test Mouse lymphoma cells L5178y 100 - 325 µg/L Negative1 (Cifone, 2001) Valid study and in compliance with OECD Guideline 
476. 
(Carveol [02.062]) Ames test (pre-incubation) S. typhimurium TA98, TA100, TA1535, TA1537 560 µg/plate Negative (Mortelmans et al., 
1986) 
 
(Carvyl acetate 
[09.215]) 
Ames test (pre-incubation) S. typhimurium TA98, TA100, TA1535, TA1537 333 µg/plate Negative (Mortelmans et al., 
1986) 
 
(L-menthyl (R,S)-3-
hydroxybutyrate) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537 and TA1538 
78, 156, 312, 625, 1250, 
2500 or 10 000 μg/plate 
Negativea,b (Morimoto, 2005) The JECFA evaluated the racemate of L-menthyl 
(R,S)-3-hydroxybutyrate. 
Reverse mutation E. coli WP2uvrA 78, 156, 312, 625, 1250, 
2500 or 10 000 μg/plate 
Negativea,b (Morimoto, 2005)  
NA: Not applicable. 
NR: Not reported. 
1 With and without S9 metabolic activation. 
2 With S9 activation. 
3 Without S9 activation. 
4 Calculated based on molecular weight of menthol = 156.3 g/mol. 
5 Marked differential toxicity was seen at dose levels above 25 µmol/plate. No observations were noted at lower dose levels. 
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In vivo mutagenicity/genotoxicity data are available for two candidate substance of the present FGE and for three supporting substances evaluated by JECFA 
at the 51st and 59th meetings. Supporting substances are listed in brackets. 
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(Menthol [02.015]) Host mediated 
mutation assay 
S. typhimurium  
TA1530 and G46; S. 
cerevisiae D3 
inoculated in mice (7-
9 animals/group) 
Gavage  0, 1.45 - 5000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Equivocal (Food and Drug Research 
Laboratories, Inc., 1975a) 
Negative results, with exception  of 
the combination S. typhimurium  
TA1530 – 5000 mg/kg bw and S. 
cerevisiae D3 – 1150 mg/kg bw/day. 
This study is considered valid, but 
the equivocal result might have  low 
relevance since the  effect was only 
observed at very high (lethal) dose 
levels. 
In vivo cytogenetic assay Male rat bone marrow 
cells 
Gavage 0, 1.45 - 3000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Negative (Food and Drug Research 
Laboratories, Inc., 1975a)            
Oral DL50 was determined as 940 
mg/kg bw. The study is considered 
valid but the negative result is of 
limited relevance, since no effect on 
mitotic index was observed. 
However, testing at higher dose 
levels may not have been possible, 
due to lethality. 
In vivo micronucleus 
assay 
B6C3F1 male mouse 
bone marrow cells 
Intra peritonal 0, 250 - 1000 mg/kg bw/day, 
during 3 days 
Negative (Shelby et al., 1993) d,l-Menthol was used. The study is 
considered valid, but the negative 
result is of limited relevance, since 
no toxicity to the bone marrow was 
observed. However, testing at higher 
dose levels was not possible, because 
the highest dose caused 50 % 
lethality. 
In vivo dominant lethal 
assay 
Male rat fertility, 
spermatozoa 
Gavage 0, 1.45 - 3000 mg/kg bw 
(single dose) 
0, 1150 mg/kg bw/day 
(repeated doses) 
Negative (Food and Drug Research 
Laboratories, Inc., 1975a) 
This study is considered valid. 
(trans-Menthone [07.176]) In vivo SMART assay D. melanogaster – flr3 
x mwh cross  
Whole body 0, 1.3 µl/disk Positive (Franzios et al., 1997) Somatic Mutation and 
Recombination Test. Only one dose 
level (1.29 μl/disk; slightlyhigher 
than the LD50) was tested. A two-fold 
increase in mutation frequency as 
compared to control was observed. 
Menthone was not recombinogenic. 
The validity of this study is unclear. 
(Cyclohexanone [07.148]) In vivo sex-linked 
recessive lethal mutation 
D. melanogaster  NR 
3 days exposure 
0, 1 μl/ml Negative (Goncharova, 1970) Article in Russian. Only an abstract 
available in English. The validity of 
this study cannot be assessed. 
Cyclohexanol [02.070] In vivo sex-linked 
recessive lethal mutation 
D. melanogaster NR 
3 days exposure 
0, 1 μl/ml Negative (Goncharova, 1970) The validity of the study cannot be 
evaluated. 
In vivo micronucleus test NMRI mouse bone 
marrow  
Oral  500 - 1500 mg/kg bw Negative (Gelbke, 1991) The study is considered valid. The 
negative result of this study is of 
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Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
limited relevance, since no bone 
marrow toxicity could be detected. 
Testing at higher dose levels might 
not have been possible due to 
observed general toxicity at the 
highest dose. 
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [09.520] 
Micronucleus test ICR mice Intra peritonal 280, 560 & 1120 mg/kg bw Negative (Gudi and Krsmanovis, 1998) Valid study in compliance with the 
OECD Guideline 474. 
Unscheduled DNA 
Synthesis 
Rat hepatocytes Intra peritonal 333.3 & 1000 mg/kg bw Negative (Durward, 2001) Valid study in compliance with the 
OECD Guideline 486.  
NR: Not reported. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  body weight  
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
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